Orgenesis Inc. ORGS
Set alert
At close · Oct 29
- YTD
- -68.87%
- 1 year
- -68.87%
- Open
- 0.91
- Prev close
- 0.0467
- Mkt cap
- 457.64K
- Vol
- 100
- Avg vol
- 997
- EPS
- -1.34
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.91
- High
- 0.91
- Forward P/E
- 1.97
- Beta
- 1.32
- Short ratio
- 2.39
- Inst. own
- 4.39%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.62
- 200-d avg
- 5.45
- 1y target
- 0.00
Key statistics
- Market cap
- 5.72M
- Enterprise value
- 17.86M
- Trailing P/E
- 0.00
- Forward P/E
- 1.97
- PEG ratio
- 0.00
- Price / sales
- 8.65
- Price / book
- 0.00
- EPS (TTM)
- -8.00
- Beta
- 1.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 662.00K
- Revenue growth
- 117.70%
- Free cash flow
- 9.71M
- Total cash
- 77.00K
- Total debt
- 13.02M
- Return on equity
- 0.00%
- Shares outstanding
- 4.77M
- Short % of float
- 1.33%
- 50-day average
- 3.62
- 200-day average
- 5.45
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -1.93 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | -2.30 | — | — |
| May 21, 2024 | Mar 1, 2024 | 0.00 | -2.90 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -4.30 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | -1.50 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 13, 2023 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Mar 21, 2023 | Benchmark | reit | — | Buy |
| Sep 25, 2019 | Benchmark | init | — | Speculative Buy |
About Orgenesis Inc.
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- orgenesis.com
News
- Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio
- Critical Contrast: UCB (OTCMKTS:UCBJF) versus Orgenesis (NASDAQ:ORGS)
- Orgenesis (NASDAQ:ORGS) Stock Price Up 300% – Time to Buy?
- Comparing eFFECTOR Therapeutics (NASDAQ:EFTR) and Orgenesis (NASDAQ:ORGS)
- Statera Biopharma (NASDAQ:STAB) vs. Orgenesis (NASDAQ:ORGS) Financial Contrast
- Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies
- Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings
- Why Maison Solutions Shares Are Trading Higher By Around 91%; Here Are 20 Stocks Moving Premarket
- Orgenesis Announces Positive Results From a Real-World Study of ORG-101 CAR-T Therapy in Patients with CD19+ Acute Lymphoblastic Leukemia
- Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally
Your note
Sign in to keep a note on ORGS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MILLER VICTOR | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 31, 2024 | 25,000 |
| SAFIER JACOB | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 31, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 5.92% | 924,806 | 1.29M | Jun 29, 2023 |
| Knoll Capital Management, LLC | 4.06% | 634,738 | 882.28K | Jun 29, 2023 |
| Redmond Asset Management, LLC | 3.71% | 579,980 | 806.17K | Jun 29, 2023 |
| Geode Capital Management, LLC | 1.32% | 206,754 | 287.39K | Jun 29, 2023 |
| Blackrock Inc. | 0.85% | 132,572 | 184.28K | Jun 29, 2023 |
| State Street Corporation | 0.57% | 88,659 | 123.24K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.63% | 566,688 | 787.70K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 1.92% | 300,650 | 417.90K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.69% | 107,562 | 128.00K | May 30, 2023 |
| iShares Micro Cap ETF | 0.34% | 53,550 | 27.26K | Aug 30, 2023 |
| Fidelity Total Market Index Fund | 0.26% | 40,821 | 48.58K | May 30, 2023 |
| Vanguard Balanced Index Fund | 0.21% | 32,261 | 44.84K | Jun 29, 2023 |